Heron Bay Capital Management Buys New Position in Cumberland Pharmaceuticals Inc. $CPIX

Heron Bay Capital Management bought a new stake in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) in the 2nd quarter, HoldingsChannel reports. The firm bought 33,251 shares of the specialty pharmaceutical company’s stock, valued at approximately $111,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Berkshire Asset Management LLC PA purchased a new stake in shares of Cumberland Pharmaceuticals during the 1st quarter valued at $692,000. Adage Capital Partners GP L.L.C. purchased a new position in Cumberland Pharmaceuticals in the first quarter worth $634,000. Informed Momentum Co LLC bought a new position in Cumberland Pharmaceuticals in the first quarter valued at $304,000. Finally, Walleye Capital LLC bought a new position in Cumberland Pharmaceuticals in the first quarter valued at $298,000. Hedge funds and other institutional investors own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Stock Performance

Cumberland Pharmaceuticals stock opened at $1.99 on Friday. The firm has a fifty day simple moving average of $2.95 and a two-hundred day simple moving average of $3.65. The company has a quick ratio of 1.17, a current ratio of 1.30 and a debt-to-equity ratio of 0.19. Cumberland Pharmaceuticals Inc. has a twelve month low of $1.04 and a twelve month high of $7.25. The company has a market capitalization of $29.69 million, a PE ratio of -9.02 and a beta of -0.46.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last announced its quarterly earnings data on Tuesday, November 4th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a negative net margin of 6.97% and a positive return on equity of 7.48%. The company had revenue of $8.29 million for the quarter.

Analyst Ratings Changes

Several equities research analysts have issued reports on CPIX shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cumberland Pharmaceuticals in a research note on Wednesday. Wall Street Zen cut Cumberland Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, August 25th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.